Advertisement
AXON vs TECH
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Bio-Techne (TECH) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) focuses on public safety technology with strong recurring revenue growth from software and AI products, while Bio-Techne (TECH) provides life sciences tools and reagents, recently subject to an acquisition agreement.
- In recent market activity, AXON has shown volatility ahead of its August 5 earnings report, with year-to-date returns lagging broader benchmarks but longer-term outperformance.
- TECH experienced sentiment shifts following the June 2026 acquisition announcement by Merck KGaA, with its stock trading near levels reflecting the proposed $73 per share cash offer.
- Both companies face upcoming earnings releases on August 5, providing potential catalysts for price movements based on results and forward guidance.
- Sector exposure differs markedly: AXON in defense and public safety with AI integration, versus TECH in biotechnology research tools amid M&A (mergers and acquisitions) activity.
- Relative performance highlights trade-offs between AXON’s growth momentum in high-valuation segments and TECH’s stability tied to acquisition terms.
Introduction
This comparison examines Axon Enterprise (AXON) and Bio-Techne (TECH) to help investors and traders assess their positioning in the current market environment. Both stocks operate in technology-driven sectors but serve distinct end markets—public safety for AXON and life sciences research for TECH. The analysis draws on recent performance trends, business fundamentals, and observable market factors to illustrate contrasts in growth profiles, risk exposures, and sentiment drivers. It is relevant for those evaluating relative opportunities in growth-oriented equities or sector-specific allocations without favoring one over the other.
AXON Overview and Recent Performance
Axon Enterprise (AXON) develops and sells conducted energy devices, body-worn cameras, and related software platforms primarily for law enforcement and public safety agencies. Its business emphasizes recurring revenue from cloud-based services and AI-enabled tools. In recent market activity, the stock has traded in a range influenced by broader equity volatility and positioning ahead of its second-quarter earnings release scheduled for August 5. Year-to-date returns stood near 7% as of late July, with one-year performance exceeding 30%. Key developments include sustained double-digit revenue growth, highlighted by first-quarter results showing 34% year-over-year increases, alongside expansions in AI products and counter-drone offerings. Sentiment has reflected analyst focus on margin expansion and recurring revenue stability amid elevated valuation multiples.
TECH Overview and Recent Performance
Bio-Techne (TECH) manufactures and distributes reagents, instruments, and proteins used in life sciences research, diagnostics, and biopharmaceutical development. The company supports academic, clinical, and industrial customers with tools for protein analysis and cell biology. In recent market activity, its stock has reflected developments around the June 2026 agreement for Merck KGaA to acquire the firm at $73 per share in cash, valued at approximately $11.3 billion. Fiscal fourth-quarter earnings are also expected around August 5. Broader performance has shown more limited upside in 2026 amid sector rotations, with trading levels consistent with acquisition-related pricing. Sentiment has incorporated the transaction’s implications for strategic positioning in growing life sciences markets, alongside ongoing product launches such as expanded AI-engineered protein portfolios.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this trending section. Available bots span diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, enabling users to review statistics such as historical returns, win rates, and drawdowns for informed selection. This resource supports traders seeking data-driven approaches tailored to individual risk preferences and market views. Explore the full range on the Trending AI Robots page for detailed bot profiles and performance data.
Head-to-Head Comparison
Axon Enterprise (AXON) and Bio-Techne (TECH) differ substantially in business models, with AXON centered on hardware-software ecosystems for public safety and TECH focused on consumables and instruments for research applications. Growth drivers for AXON include AI adoption in law enforcement and recurring subscription revenue, while TECH benefits from biopharma R&D spending and recent M&A (mergers and acquisitions) activity. Recent momentum shows AXON with stronger multi-year returns but higher valuation sensitivity, contrasted by TECH’s more stable trajectory tied to acquisition terms. Risk factors include AXON’s exposure to government budgets and regulatory shifts versus TECH’s dependence on research funding cycles and integration outcomes post-acquisition. Sector exposure places AXON in industrial-defense themes with AI tailwinds, while TECH aligns with healthcare-biotech innovation. Market sentiment for AXON reflects earnings anticipation and product pipeline strength; for TECH, it centers on transaction certainty and earnings visibility.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recurring revenue segments, stability from acquisition structuring, and relative positioning ahead of earnings, Tickeron’s AI would currently assign a probabilistic edge to Bio-Techne (TECH) for nearer-term resilience, while noting Axon Enterprise (AXON)’s potential for momentum if growth metrics hold. This assessment draws from verifiable performance patterns and catalysts rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and TECH is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- TECH’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 4 bearish.
- TECH’s TA Score: 4 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +10.87% price change this week, while TECH (@Biotechnology) price change was +0.03% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +11.82%. For the same industry, the average monthly price growth was -6.89%, and the average quarterly price growth was +1.16%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.86%. For the same industry, the average monthly price growth was -6.20%, and the average quarterly price growth was +2821.81%.
Reported Earning Dates
AXON is expected to report earnings on Aug 05, 2026.
TECH is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Aerospace & Defense (+11.82% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+4.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | TECH | AXON / TECH | |
| Capitalization | 48.9B | 11.2B | 437% |
| EBITDA | 320M | 257M | 125% |
| Gain YTD | 6.915 | 22.973 | 30% |
| P/E Ratio | 244.84 | 103.00 | 238% |
| Revenue | 2.98B | 1.21B | 246% |
| Total Cash | 737M | 210M | 351% |
| Total Debt | 1.83B | 290M | 630% |
AXON | TECH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 56 | 100 | |
SMR RATING 1..100 | 82 | 85 | |
PRICE GROWTH RATING 1..100 | 42 | 19 | |
P/E GROWTH RATING 1..100 | 35 | 17 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TECH's Valuation (65) in the Biotechnology industry is in the same range as AXON (90). This means that TECH’s stock grew similarly to AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (56) in the Biotechnology industry is somewhat better than the same rating for TECH (100). This means that AXON’s stock grew somewhat faster than TECH’s over the last 12 months.
AXON's SMR Rating (82) in the Biotechnology industry is in the same range as TECH (85). This means that AXON’s stock grew similarly to TECH’s over the last 12 months.
TECH's Price Growth Rating (19) in the Biotechnology industry is in the same range as AXON (42). This means that TECH’s stock grew similarly to AXON’s over the last 12 months.
TECH's P/E Growth Rating (17) in the Biotechnology industry is in the same range as AXON (35). This means that TECH’s stock grew similarly to AXON’s over the last 12 months.
| AXON | TECH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 65% | N/A |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 60% |
| Advances ODDS (%) | 2 days ago 74% | 3 days ago 70% |
| Declines ODDS (%) | 7 days ago 70% | 13 days ago 73% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 80% | 2 days ago 48% |
Advertisement